What is Transarterial Radioembolization (TARE)



Liver malignancy, be it primary tumors like Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma, is one of the top five most common cancers worldwide and is also a frequent cause of cancer-related mortality. In most of the cases, Hepatocellular Carcinoma (HCC) is often diagnosed late in the intermediate-advanced stage (stage B and C). Because of this often-late diagnosis, radical therapy doesn’t offer much success. While a few curative and/ or palliative therapies might help, but they are not often characterized by a favorable safety or efficacy ratio. Hence for this intermediate to advanced stages of HCC, internal radionuclide therapy is emerging as a good therapeutic option. And according to several studies, Transarterial Radioembolization (TARE) or intra-arterial injection of a radiolabeled embolising agent has led to extremely promising results, both in terms of demonstration of a good tolerability profile and disease control.

Transarterial Radioembolization (TARE) is also simply known as Radioembolization is a combination of Radiation Therapy and a procedure known as Embolization – a minimally invasive treatment in which blood vessels are blocked off to prevent blood flow. In TARE, tiny beads of glass or resin known as microspheres are administered inside the blood vessels that are feeding a tumor so that the supply of blood to the cancer cells can be blocked off. These microspheres are loaded with a radioactive compound – either Yttrium90 or Lipiodol labelled with iodine131 or rhenium188. Once they get lodged at the tumor site, they deliver a high dose of radiation to the tumor without affecting the normal tissues.

TARE is a palliative treatment (it means that it does not provide a cure) that helps slow down the disease growth and also helps alleviate symptoms. It is often used as a treatment option for patients who cannot undergo other treatment options such as liver surgery or liver transplantation.


Read More at What is Transarterial Radioembolization (TARE)

Comments

Post a Comment

Popular posts from this blog

Exploring the Technological Frontiers: Unveiling the Siemens Healthineers Biograph Vision PET/CT

Introducing the groundbreaking BEYOND DIGITAL PET/CT - SIEMENS HEALTHINEERS BIOGRAPH VISION, a medical imaging system that sets new standards in precision and efficiency. In the realm of precision oncology, where even the smallest details hold immense significance, the introduction of advanced digital PET-CT has revolutionized cancer diagnosis. This state-of-the-art imaging system, the BEYOND DIGITAL PET/CT - SIEMENS HEALTHINEERS BIOGRAPH VISION, is far ahead of conventional PET-CT scans, offering a host of exceptional features that have transformed the field of oncology. Now, let's explore its remarkable benefits: The BIOGRAPH VISION boasts the world's fastest time of flight, delivering unprecedented scanning speed, reducing the time taken for comprehensive imaging. Its FlowMotion Technology ensures a seamless and continuous scanning process, enhancing patient comfort while achieving faster and more accurate results. Wholebody Dynamic Imaging capabilities allow healthcare prof
Read more

Everything You Need To Know About Alpha PSMA Therapy

According to the  World Cancer Research Fund , Prostate Cancer is not only one of the most common malignancy in men but also one of the most commonly occurring cancer overall. Prostate Cancer is also the fifth leading cause of death from cancer in men. Disease progression and metastatic spread signifies the beginning of a lethal form of the disease – metastatic castration resistant prostate cancer (mCRPCa). The incidence of prostate cancer increases proportionally with age, especially in men above 60 years of age. Studies have also shown that incidence of prostate cancer also depend on demographics and racial prevalence – prostate cancer has a low incidence in Asia (3-8 per 100,000 men per year), an intermediate incidence in Africa and Eastern Europe, and a higher incidence in North America and Western Europe. While conventional treatment modalities for localized prostate cancers include surgery, chemotherapy, cryotherapy, brachytherapy with radioactive seeds, and usage of external
Read more

Tare Vs Tace For Hepatocellular Carcinoma and Net Patients

  The incidence of Hepatocellular Carcinoma or HCC has been increasing over the past several years and several studies have projected that the incidence of HCC will continue to rise in the coming years. Transarterial Chemoembolisation or TACE has been the initial treatment modality for HCC and has a huge body of evidence from several studies and clinical trials. Therefore, for long TACE has been a preferred treatment algorithm for unresectable HCC. However, as the experience of  Transarterial Radioembolisation or TARE  has evolved, it is playing an increasingly important role in the treatment of unrespectable HCC. Studies and trials have shown that TARE has many potential advantages over TACE and there is now substantial evidence to favor TARE over TACE. The many potential advantages of TARE when compared with TACE are as below: · Several studies have shown a statistically significant overall survival advantage with TARE as compared to TACE. · TARE has better health-related quality-of-
Read more